Bayer and Onyx Launch Educational Program to Raise Awareness About Liver Cancer and Its Ri...( New Survey Quantifies Misperceptio...),Health

New Survey Quantifies Misperceptions about Liver Cancer in the United

States

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- A new survey of more than 1,000 American adults revealed that general knowledge regarding liver cancer risk factors and treatment options is limited, even among individuals with a connection to the disease. According to the GfK Roper survey, among those aware of the disease approximately 60 percent are unable to name a single symptom associated with liver cancer and more than 40 percent are unaware of treatment options.

To address this lack of knowledge and awareness of liver cancer in the United States, Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), in partnership with leading advocacy organizations the American Liver Foundation (ALF) and Vital Options International, today announced the launch of Living with Liver Cancer -- a program designed to educate patients and caregivers about liver cancer signs and symptoms, risk factors, diagnosis, screening and available treatment options.

The centerpiece of the program is the Living with Liver Cancer Web site (http://www.LivingwithLiverCancer.com), which serves as a resource for people seeking more information about liver cancer and liver disease. To expand access and availability of the program to a wider audience, information on the Web site will be translated into several different languages, including Chinese and Spanish. More than 600,000 cases of liver cancer are diagnosed worldwide each year, including 15,000 cases in the United States.(1,2)

"There is a need for greater understa
'/>"/>